MAXCYTE INC

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

MXCT$1.30+3.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)


· · Three Months Ended September 30, · · · Nine Months Ended September 30,
· 2024 · 2023 · · 2024 · 2023
Revenue	$8,164	$8,004	$29,934	$25,623
Cost of goods sold	1,928	793	4,819	3,169
Gross profit	6,236	7,211	25,115	22,454

Operating expenses:
Research and development	5,316	6,264	17,613	17,975
Sales and marketing	6,207	7,046	20,188	19,778
General and administrative	7,745	6,820	22,487	21,982
Depreciation and amortization	1,021	1,033	3,123	2,922
Total operating expenses	20,289	21,163	63,411	62,657
Operating loss	(14,053)	(13,952)	(38,296)	(40,203)

Other income:
Interest income	2,496	2,701	7,838	7,558
Total other income	2,496	2,701	7,838	7,558
Loss before income taxes	(11,557)	(11,251)	(30,458)	(32,645)
Provision for income taxes	—	—	—	—
Net loss	$(11,557)	$(11,251)	$(30,458)	$(32,645)
Basic and diluted net loss per share	$(0.11)	$(0.11)	$(0.29)	$(0.32)
Weighted-average shares outstanding, basic and diluted	105,109,603	103,449,715	104,614,679	103,121,997

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.